Executive Summary

People with chronic diseases account for 90% of the US' $3.3 trillion in annual healthcare spending, making improving chronic disease treatment a huge savings opportunity for insurers. And digital therapeutics—a burgeoning category of software that replaces or complements the existing treatment of a disease — is one of the few clinically validated digital health technologies, with early trials demonstrating the tech can improve chronic disease outcomes and medication adherence, a $300 billion problem. While the largest US insurers have showed some recent interest in digital therapeutics with partnerships, this space is largely opaque.

Three Key Questions This Report Will Answer:

• For which conditions are digital therapeutics best-equipped to improve patient outcomes and lower medical costs?
• Who are the leading digital therapeutics companies, and what's their value proposition to health insurers and/or pharma companies?
• What are insurers and pharma firms currently doing to tap into this opportunity? What are some early insights for best practices for insurers? What's next for the space?

WHAT’S IN THIS REPORT? In this report, Business Insider Intelligence will explore the drivers fueling growth in the DTx market, identify the leading DTx market players, and unpack the different DTx distribution models. We will also assess both the opportunities and risks DTx companies and their products pose to payers, pharmaceutical companies, and medtech firms. Finally, we will forecast what's next in the DTX space and outline the barriers holding DTx firms back to help stakeholders navigate the crowding field and develop strategies to capture a piece of the DTx pie.